Ascelia Pharma publishes Annual Report for 2020


Ascelia Pharma’s Annual Report has now been published and is available on the company’s website.

"In 2020, despite the ongoing Covid-19 pandemic, we continued to advance the clinical development program and commercial preparations of our novel Phase 3 contrast agent Mangoral. We also accelerated the Phase 2 preparations for our oral chemotherapy tablet Oncoral.

Our focus in 2021 is on the ongoing Phase 3 study SPARKLE, the preparations to make Mangoral available to patients in need, and to initiate the clinical Phase 2 for Oncoral. We work constantly to create stakeholder value, and the development in 2020 un­derlines the progress we have made”, said Magnus Corfitzen, CEO at Ascelia Pharma.